Pandemic Demonstrates Importance of Strong Clinical Trial
Design Quality

Pandemic Demonstrates Importance of Strong Clinical Trial Design Quality

Mon, 19 Jul 2021

If we as an industry learn anything from battling the COVID-19 pandemic, David Burrow, PharmD, JD, director of the Office of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research at the U.S. Food and Drug Administration (FDA), has something high atop his wish list. “I hope we recognize the need to build quality into clinical research from the initial concept all the way through to operations,” Burrow says. “The pandemic demonstrated the need for training and focus on Good Clinical Practices, and not just for ideal situations, but for when things go sideways” such as during the pandemic, adds Burrow, who will offer insights on how to handle FDA Form 483s (Inspection Observations) and Warning Letters, along with shout outs to his FDA colleagues for a job well done, [in a session for the ACRP 2021 virtual conference](https://2021.acrpnet.org/2021-calendar/2021/9/16/cder-bimo-compliance-and-enforcement-what-you-need-to-know) in September. “The work of FDA inspectors during the pandemic was phenomenal,” Burrow says, noting how they helped avert “what might have been a catastrophic slowdown” in inspections and the overall drug approval process. > CDER BIMO Compliance and Enforcement – What You Need to Know! > > Join Burrow on Thursday, September 16, during the third and final installment of ACRP 2021, for an exploration of how the clinical research industry can make the FDA inspection experience a positive one. Take away practical approaches to working with the FDA during an inspection, responding to 483s after an inspection, and responding to subsequent regulatory correspondence. > > [View Session Details >](https://2021.acrpnet.org/2021-calendar/2021/9/16/cder-bimo-compliance-and-enforcement-what-you-need-to-know) Burrow also applauds the results of an FDA report issued in May, “[Resiliency Roadmap for FDA Inspectional Oversight](https://www.fda.gov/media/148197/download),” outlining the agency’s inspectional activities during the COVID-19 pandemic and its detailed plan to move toward a more consistent state of operations. “Like most organizations around the world, the FDA experienced unprecedented and unique challenges during the SARS-CoV-2 pandemic. In particular, our inspection, surveillance, and compliance activities were significantly impacted,” acting FDA Commissioner Janet Woodcock, MD, said when releasing the report. “The FDA fully understands the importance of getting back to a more consistent state of inspectional capacity. This plan provides the public with a transparent picture of both the successes and challenges we’ve faced in these areas over the past year, as well as our plan moving forward. We want to assure the American public that we have used a variety of tools to oversee the regulated industry and ensure that Americans continue to have access to safe food and high-quality, FDA-regulated products.” However, it’s not just the pandemic that has challenged the clinical trial industry, Burrow adds. He cites workforce shortages and high turnover rates in some areas of the clinical trial enterprise as potential obstacles. “ACRP’s [Partners in Workforce Advancement initiative](https://acrpnet.org/acrp-partners-in-workforce-advancement/acrp-partners-in-workforce-advancement-grow-the-workforce/) has been making this important point for some time,” says Burrow, a member of the initiative’s executive committee. Given trends in workforce turnover, in particular, Burrow believes training and educational programs such as the ACRP 2021 virtual conference are more vital than ever before, because new entrants need to learn the best ways to conduct quality clinical trials. Still, if many things have changed since the pandemic upended the clinical trial industry, Burrow can point to one area that hasn’t altered an iota: The importance of timely responses to FDA Form 483s and Warning Letters. “That hasn’t changed at all because of COVID,” he says. Author: Michael Causey The post [Pandemic Demonstrates Importance of Strong Clinical Trial Design Quality](https://acrpnet.org/2021/07/19/pandemic-demonstrates-importance-of-strong-clinical-trial-design-quality/) appeared first on [ACRP](https://acrpnet.org/).

Related Articles

New method for tracking RNA with fluorescence

New method for tracking RNA with fluorescence

Clinical Trial Manager Gets Candid About The Research
Industry, Becoming A Generalist Ep.550

Clinical Trial Manager Gets Candid About The Research Industry, Becoming A Generalist Ep.550

Fast-Tracking New Treatments into Clinical Trials for
Children with Cancer

Fast-Tracking New Treatments into Clinical Trials for Children with Cancer

Unpicking Salmonella's survival strategies

Unpicking Salmonella's survival strategies

The Niche Episode 068 – Eli Lilly + ProQR, Sanofi + Kadmon,
Lycia, BlueBird + 2seventy, Mammoth

The Niche Episode 068 – Eli Lilly + ProQR, Sanofi + Kadmon, Lycia, BlueBird + 2seventy, Mammoth

Full Interview With The Clinical Trials Guru on California,
Money and Clinical Research

Full Interview With The Clinical Trials Guru on California, Money and Clinical Research

Another Way Job Seekers Can Get Their Foot In The Door In
The Clinical Research Industry

Another Way Job Seekers Can Get Their Foot In The Door In The Clinical Research Industry

Jumpcode Genomics and TGen collaborate on genomic sequencing
of SARS-CoV-2

Jumpcode Genomics and TGen collaborate on genomic sequencing of SARS-CoV-2

Preventing Malaria: A Glimmer of Hope?

Preventing Malaria: A Glimmer of Hope?

Bacterial survival under starvation conditions

Bacterial survival under starvation conditions

MD Anderson and SNIPR BIOME join forces to advance new
CRISPR-based microbiome therapeutics

MD Anderson and SNIPR BIOME join forces to advance new CRISPR-based microbiome therapeutics

Shining (Invisible) Light On Viral Pathogens: Virucidal
Contamination Control Strategies Using UV-C Light

Shining (Invisible) Light On Viral Pathogens: Virucidal Contamination Control Strategies Using UV-C Light

Return of the mammoth? George Church-backed company launches
with $15 million for elephant-sized quest

Return of the mammoth? George Church-backed company launches with $15 million for elephant-sized quest

Burnout Threatens to Undermine Clinical Trial Workforce
Productivity

Burnout Threatens to Undermine Clinical Trial Workforce Productivity

Researchers discover transposon-encoded RNA-guided nucleases
with potential for genome editing

Researchers discover transposon-encoded RNA-guided nucleases with potential for genome editing

First rat model recapitulates all disabling alterations
experienced by patients with Morquio A disease

First rat model recapitulates all disabling alterations experienced by patients with Morquio A disease

Phage therapy: The era of personalized medicine

Phage therapy: The era of personalized medicine

Why You Should Get Your Start At a Small Biotech Company
(Part 3)

Why You Should Get Your Start At a Small Biotech Company (Part 3)

New precision-guided sterile insect technique designed to
control disease-spreading mosquitoes

New precision-guided sterile insect technique designed to control disease-spreading mosquitoes

Collaborative Development Begins on Novel Digital Data Flow
Solution for Study Start-Up

Collaborative Development Begins on Novel Digital Data Flow Solution for Study Start-Up

Patients Deserve Remote Clinical Trial Options

Patients Deserve Remote Clinical Trial Options

‘All of Us’ Program Taps New Partners to Promote Trial
Diversity

‘All of Us’ Program Taps New Partners to Promote Trial Diversity

Many Unproven Cancer Drugs Continue to be Recommended for
Patients

Many Unproven Cancer Drugs Continue to be Recommended for Patients

What Data Can Clinical Research Sites Collect About
Themselves To Remain Relevant Next Decade?

What Data Can Clinical Research Sites Collect About Themselves To Remain Relevant Next Decade?

ICH Q12 meets FDA acceptance

ICH Q12 meets FDA acceptance

UC San Diego researchers receive $6 million NIH grant to
study insulin-producing cells

UC San Diego researchers receive $6 million NIH grant to study insulin-producing cells

New gene-delivering workhorse could make gene therapy safer,
more effective for muscle diseases

New gene-delivering workhorse could make gene therapy safer, more effective for muscle diseases

We Answer Questions From A Clinical Research Coordinator Who
Probably Works For A Bad Site

We Answer Questions From A Clinical Research Coordinator Who Probably Works For A Bad Site